Intercytex Senior Management Team
Paul Kemp PhD, Chief Executive and Chief Scientific Officer
Paul has been involved in commercial regenerative medicine for over 20 years. He has a successful track record in virtually all aspects of the business from founding biotech companies, raising significant public and private funding in Europe, US and Asia; designing, building and operating GMP facilities in the US and UK; designing and operating clinical trials including extensive interactions with the MHRA, EMA and FDA; operating multi national, multi centre Phase I, II and III studies, and finally, launching marketing and selling cell based products both in the US and UK. He is the inventor on several patents related to multiple regenerative medicine products both in development and on the market and publishes and presents widely in the field. Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.
John Lovelady PhD, Chief Operating Officer
John has over 25 years of experience in the production of biologicals, the management of GMP facilities, QA/QC and regulatory compliance. He was previously Director of GMP Manufacturing Operations at Cobra Biomanufacturing plc, a contract manufacturer of clinical grade proteins, DNA and viruses. Prior to Cobra he was an independent consultant to the industry, VP of Technical R&D and Manufacturing at Centelion (formerly Gencell, a Paris-based, French biopharmaceutical/gene therapy company spun out from Aventis), VP Operations at Genzyme Corporation (UK subsidiary of a US biotechnology company), Fermentation Manager at Fermentech Ltd (a private fermentation facility) and he started his career as a research scientist at Technoferm Developments Ltd (Porton Down). John has a BSc in Applied Biology and a PhD in enzyme biosynthesis.
Mark Caldwell BA (Oxon) MA (City), Chairman.
Mark worked in the City in the 1990s as a Corporate and Structured Financier. Since 2000 he has run Bluemantle, the NW-based asset manager focussed on real estate and life sciences investments which has a portfolio of over £100m. He has extensive contacts across the public and private sectors and considerable experience of operational business management.